Vanda Pharmaceuticals shares fell about 10% premarket after the FDA said it cannot approve the company's application to expand HETLIOZ for jet lag disorder. While trial results were positive, regulators said the study design did not reflect real-world travel conditions. Vanda disputed the assessment, citing the drugs' safety record and established research methods.